NCT07557420

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-07-20Est. Completion: 2028-09-19

Enrollment target: 19 participants

Locations

Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Chengdu, China
Research Site, Dongguan, China
Research Site, Jinan, China
Research Site, Shanghai, China
Research Site, Shijiazhuang, China
Research Site, Taiyuan, China
Research Site, Wenzhou, China
Research Site, Wuhan, China

Contact

Alexion Pharmaceuticals, Inc. (Sponsor)clinicaltrials@alexion.com 1-855-752-2356

Other microbiome trials you might be interested in

Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum DisorderPhase 2Recruiting

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Interleukin-2 (IL-2) is an essential cytokine for T-cell proliferation. Low-dose IL-2 has been shown to increase the pro…

Beijing, ChinaEst. completion Aug 15, 2028

View Trial →

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune DiseasePhase 1Recruiting

Progressive Multiple Sclerosis (PMS)Neuromyelitis OpticaMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseAutoimmune EncephalitisStiff-Person Syndrome

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary effi…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.